Skip to Content

Are you based in North America? If yes, switch to our North American website →

ALK Breakapart

Applications
pathology
Catalogue Numbers
LPS 019 (10 tests)
LPS 019-S (5 tests)

Transforming rearrangements of the Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene at 2p23 have been recognised in a subset of human haematological and solid malignancies1.

ALK fuses with Nucleophosmin (NPM1) in anaplastic lymphoma, resulting in constitutive kinase activity, which inhibits apoptosis and promotes cellular proliferation2. The rearrangement of ALK has now also been implicated in the development of Non-Small Cell Lung Cancer (NSCLC) as a result of an inversion involving chromosome 2, inv(2)(p21p23), causing ALK to fuse with the EML4 gene2. The ALK gene is frequently involved in translocations of chromosome 2 that lead to gene fusions in a variety of different malignancies, including neuroblastomas and myofibroblastic tumours3.

It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes. Janet M. Cowan, PhD, Director of the Cytogenetics Laboratory at Tufts Medical Center

References

1. Marileila Varella-Garcia et al., Association of molecular pathology: Solid Tumour Review. 2010

2. Takeuchi K et al., Clin Cancer Res. 2008;14(20):6618-6624

3. Lin et al., Mol Cancer Res. 2009;7(9):1466-1476

Microscope Images

ALK Breakapart magnified
Area of Interest*
Lung Cancer

Disclaimer

This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.